Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,494JPY
21 Jun 2018
Change (% chg)

-- (--)
Prev Close
¥4,494
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,667,403
52-wk High
¥6,693
52-wk Low
¥4,203

Latest Key Developments (Source: Significant Developments)

Takeda Says Entered Into Term Loan Credit Agreement For Up To $7.5 Billion For Shire Acquisition
Friday, 8 Jun 2018 02:01am EDT 

June 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA SAYS ENTERED INTO TERM LOAN CREDIT AGREEMENT FOR UP TO $7.5 BILLION FOR SHIRE ACQUISITION.  Full Article

Myovant Sciences' Unit Entered Agreement With Takeda Regarding Relugolix
Tuesday, 5 Jun 2018 06:39am EDT 

June 5 (Reuters) - Myovant Sciences Ltd: :MYOVANT SCIENCES - EFFECTIVE MAY 30, CO'S UNIT ENTERED COMMERCIAL MANUFACTURING & SUPPLY AGREEMENT WITH TAKEDA PHARMACEUTICAL REGARDING RELUGOLIX.MYOVANT - PURSUANT TO AGREEMENT, TAKEDA AGREED TO SUPPLY TO MSG & MSG AGREED TO GET FROM TAKEDA CERTAIN QUANTITIES OF RELUGOLIX DRUG SUBSTANCE.MYOVANT- RELUGOLIX DRUG SUBSTANCE SUPPLY & OBTAINMENT WITH TAKEDA AS PER AGREED-UPON QUALITY SPECIFICATIONS, IN ORDER TO COMMERCIALIZE RELUGOLIX.  Full Article

Wave Life Sciences Reports Qtrly Loss Per Share $1.26
Wednesday, 9 May 2018 08:00am EDT 

May 9 (Reuters) - WAVE Life Sciences Ltd ::WAVE LIFE SCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.WAVE LIFE SCIENCES LTD QTRLY LOSS PER SHARE $1.26.WAVE LIFE SCIENCES LTD - ENDED Q1 OF 2018 WITH $110.5 MILLION IN CASH AND CASH EQUIVALENTS.WAVE LIFE SCIENCES - EXPECTS CASH, CASH EQUIVALENTS, $170.0 MILLION CASH FROM TAKEDA IN APRIL, ENABLE FUNDING OPERATING, CAPEX REQUIREMENTS TO 2020 END.  Full Article

Takeda Pharmaceutical says execution of bridge loan agreement for Shire plc acquisition
Tuesday, 8 May 2018 02:38am EDT 

May 8(Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says it signed 364-Day Bridge Credit Agreement worth up to $30.85 billion for Shire plc acquisition on May 8 .  Full Article

Takeda Responds to Media Reports About CEO's Comments On Possible Offer For Shire
Friday, 6 Apr 2018 12:35pm EDT 

April 6 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::STATEMENT REGARDING PRESS REPORTS.‍NOTES MEDIA REPORTS ABOUT COMMENTS ATTRIBUTED TO TAKEDA'S CEO CHRISTOPHE WEBER REGARDING COMPANY'S POSSIBLE OFFER FOR SHIRE PLC​.‍"CONFIRMS THAT WEBER'S COMMENTS WERE, HOWEVER, ALIGNED WITH STATEMENTS IN OUR PREVIOUS PRESS RELEASES"​.‍ PRIOR STATEMENTS "CLEARLY DEFINED STRATEGIC AND FINANCIAL OBJECTIVES CORE TO ITS DISCIPLINED APPROACH TO ACQUISITIONS".‍"ANY POTENTIAL OFFER FOR SHIRE, IF MADE, WOULD HAVE TO ALIGN WITH THE STRICT INVESTMENT CRITERIA"​.  Full Article

Rhythm Pharma Announces Licensing Agreement With Takeda
Monday, 2 Apr 2018 08:00am EDT 

April 2 (Reuters) - Rhythm Pharmaceuticals Inc ::RHYTHM PHARMACEUTICALS ANNOUNCES LICENSING AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF PRECLINICAL TREATMENT FOR PRADER-WILLI SYNDROME.RHYTHM PHARMACEUTICALS INC - ‍RHYTHM EXPECTS TO FILE INVESTIGATIONAL NEW DRUG APPLICATION IN Q1 OF 2020​.RHYTHM PHARMACEUTICALS INC - ‍ ACQUIRED EXCLUSIVE, WORLDWIDE RIGHTS FROM TAKEDA TO DEVELOP AND COMMERCIALIZE T-3525770 (NOW RM-853)​.RHYTHM PHARMACEUTICALS INC - ‍UNDER TERMS, CO WILL ASSUME SOLE RESPONSIBILITY FOR GLOBAL PRODUCT DEVELOPMENT AND COMMERCIALIZATION OF RM-853​.RHYTHM PHARMACEUTICALS-‍ TAKEDA TO GET UPFRONT PAYMENT OF $5 MLN IN CO'S STOCK, BACK-END DEVELOPMENT MILESTONES, SINGLE-DIGIT ROYALTIES ON RM-853 SALES​.RHYTHM PHARMACEUTICALS INC - ‍WILL EXPLORE OPPORTUNITIES TO EVALUATE SETMELANOTIDE AND RM-853 IN COMBINATION, AS THERE MAY BE COMPLEMENTARY EFFECTS​​.  Full Article

Shire Confirms It Has Not Received Approach From Takeda
Wednesday, 28 Mar 2018 08:30am EDT 

March 28 (Reuters) - Shire Plc ::REG-SHIRE PLC : STATEMENT RE POSSIBLE OFFER.‍NOTES ANNOUNCEMENT BY TAKEDA PHARMACEUTICAL COMPANY LIMITED​.SHIRE CONFIRMS THAT IT HAS NOT RECEIVED AN APPROACH FROM TAKEDA..  Full Article

Takeda Pharmaceutical Says Considers Making Approach To Shire On Possible Offer
Wednesday, 28 Mar 2018 05:23am EDT 

March 28 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::‍TAKEDA STATEMENT REGARDING SHIRE PLC​.‍CONFIRMS THAT IT IS CONSIDERING MAKING AN APPROACH TO SHIRE REGARDING A POSSIBLE OFFER .CONSIDERATION OF SUCH AN OFFER IS AT A PRELIMINARY AND EXPLORATORY STAGE AND NO APPROACH HAS BEEN MADE TO BOARD OF SHIRE.‍TAKEDA MUST, BY NO LATER THAN 5.00 P.M. ON 25 APRIL 2018, EITHER ANNOUNCE A FIRM INTENTION TO MAKE AN OFFER OR NOT​.  Full Article

Walgreens Boots Alliance Appoints James Kehoe Global Chief Financial Officer
Thursday, 8 Mar 2018 06:00am EST 

March 8 (Reuters) - Walgreens Boots Alliance Inc ::WALGREENS BOOTS ALLIANCE APPOINTS JAMES KEHOE GLOBAL CHIEF FINANCIAL OFFICER.WALGREENS BOOTS ALLIANCE APPOINTS JAMES KEHOE GLOBAL CHIEF FINANCIAL OFFICER.WALGREENS BOOTS ALLIANCE INC - ‍KEHOE PREVIOUSLY SERVED AS CHIEF FINANCIAL OFFICER AND BOARD DIRECTOR OF TAKEDA PHARMACEUTICAL COMPANY LIMITED​.WALGREENS BOOTS ALLIANCE INC - ‍KEHOE TAKES OVER FROM GEORGE FAIRWEATHER​.WALGREENS BOOTS ALLIANCE INC - KEHOE WILL SUCCEED GEORGE FAIRWEATHER.WALGREENS BOOTS ALLIANCE INC - ‍FAIRWEATHER TO SERVE AS SENIOR ADVISOR TO CEO STEFANO PESSINA FOR BUSINESS DEVELOPMENT AND FINANCE​.WALGREENS BOOTS ALLIANCE INC - ‍APPOINTMENT OF JAMES KEHOE EFFECTIVE JUNE 1​.  Full Article

Riken Vitamin announces shareholding structure change
Wednesday, 21 Feb 2018 03:56am EST 

Feb 21(Reuters) - Riken Vitamin Co Ltd <4526.T>:Says its top shareholder Takeda Pharmaceutical Company Limited <<<4502.T>>> will cut voting power in the company to 5.4 percent from 12.6 percent, and will become the third biggest shareholder of the company, effective Feb. 27.  Full Article

Deals of the day-Mergers and acquisitions

June 11 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday: